Summary of safety and efficacy of COVID-19 vaccination in
patients with multiple sclerosis

J 2023

Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis

PERNICOVÁ, Eva, Petra MACOUNOVA, Martin KRSEK a Rastislav MADAR

Základní údaje

Originální název

Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis

Autoři

PERNICOVÁ, Eva (203 Česká republika, garant, domácí), Petra MACOUNOVA (203 Česká republika), Martin KRSEK (203 Česká republika, domácí) a Rastislav MADAR (203 Česká republika)

Vydání

EUROPEAN NEUROLOGY, SWITZERLAND, KARGER, 2023, 0014-3022

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30210 Clinical neurology

Stát vydavatele

Švýcarsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 2.400 v roce 2022

Kód RIV

RIV/00216224:14110/23:00130654

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1159/000529982

UT WoS

000947309800001

Klíčová slova anglicky

COVID-19 vaccination; multiple sclerosis

Štítky

14110525, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 30. 1. 2024 08:11, Mgr. Tereza Miškechová

Anotace

V originále

Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over the world. Understanding the risk of this disease is of high importance in patients with multiple sclerosis (MS) as they represent a vulnerable population through their treatment with disease-modifying therapies (DMTs). Infective episodes may trigger relapses and lead to deterioration of the health condition. Summary: Vaccination is an important preventive measure against infectious diseases. In MS patients concerns have been raised about the effectiveness of vaccines in patients on various immunomodulatory drugs and about their possible adverse effects including impairment of neurological functions. The objective of this article is to summarize the current knowledge on immune responses to the COVID-19 vaccines and their safety in MS patients and to provide practical guidance based on the data available to date.Key Messages: Although MS is not associated with a higher risk of COVID-19, this infection can trigger relapses or pseudo-relapses. Vaccines against SARS-CoV-2 are recommended for all MS patients who are not in the active phase of the disease, despite the fact that there is still a lack of long-term reliable data on the effectiveness and safety of vaccines against COVID-19. Some DMTs can reduce vaccine humoral responses, but might still provide some protection and adequate T cell response. To optimize the effectiveness of vaccination, the ideal timing of vaccine application and DMTs dosing regimen is crucial.

Citovat

PERNICOVÁ, Eva, Petra MACOUNOVA, Martin KRSEK a Rastislav MADAR. Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis. EUROPEAN NEUROLOGY. SWITZERLAND: KARGER, 2023, roč. 86, č. 4, s. 263-276. ISSN 0014-3022. Dostupné z: https://dx.doi.org/10.1159/000529982.

@article{2278169,
   author = {Pernicová, Eva and Macounova, Petra and Krsek, Martin and Madar, Rastislav},
   article_location = {SWITZERLAND},
   article_number = {4},
   doi = {http://dx.doi.org/10.1159/000529982},
   keywords = {COVID-19 vaccination; multiple sclerosis},
   language = {eng},
   issn = {0014-3022},
   journal = {EUROPEAN NEUROLOGY},
   title = {Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis},
   url = {https://www.karger.com/Article/Abstract/529982},
   volume = {86},
   year = {2023}
}

TY  - JOUR
ID  - 2278169
AU  - Pernicová, Eva - Macounova, Petra - Krsek, Martin - Madar, Rastislav
PY  - 2023
TI  - Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis
JF  - EUROPEAN NEUROLOGY
VL  - 86
IS  - 4
SP  - 263-276
EP  - 263-276
PB  - KARGER
SN  - 00143022
KW  - COVID-19 vaccination
KW  - multiple sclerosis
UR  - https://www.karger.com/Article/Abstract/529982
N2  - Background: The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic represents one of the most challenging issues that have recently influenced everyday life in countries all over the world. Understanding the risk of this disease is of high importance in patients with multiple sclerosis (MS) as they represent a vulnerable population through their treatment with disease-modifying therapies (DMTs). Infective episodes may trigger relapses and lead to deterioration of the health condition. Summary: Vaccination is an important preventive measure against infectious diseases. In MS patients concerns have been raised about the effectiveness of vaccines in patients on various immunomodulatory drugs and about their possible adverse effects including impairment of neurological functions. The objective of this article is to summarize the current knowledge on immune responses to the COVID-19 vaccines and their safety in MS patients and to provide practical guidance based on the data available to date.Key Messages: Although MS is not associated with a higher risk of COVID-19, this infection can trigger relapses or pseudo-relapses. Vaccines against SARS-CoV-2 are recommended for all MS patients who are not in the active phase of the disease, despite the fact that there is still a lack of long-term reliable data on the effectiveness and safety of vaccines against COVID-19. Some DMTs can reduce vaccine humoral responses, but might still provide some protection and adequate T cell response. To optimize the effectiveness of vaccination, the ideal timing of vaccine application and DMTs dosing regimen is crucial.
ER  -

PERNICOVÁ, Eva, Petra MACOUNOVA, Martin KRSEK a Rastislav MADAR. Summary of safety and efficacy of COVID-19 vaccination in patients with multiple sclerosis. \textit{EUROPEAN NEUROLOGY}. SWITZERLAND: KARGER, 2023, roč.~86, č.~4, s.~263-276. ISSN~0014-3022. Dostupné z: https://dx.doi.org/10.1159/000529982.

Podrobný výpis o publikaci